Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in ...
GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 ...
The US Food and Drug Administration said Thursday that it has approved the first vaccine to prevent disease caused by the chikungunya virus. Chikungunya, a mosquito-borne disease whose name in the ...
The first vaccine to prevent infection with the chikungunya virus was approved by the U.S. Food and Drug Administration on Thursday. The single-dose shot, known as Ixchiq, is approved for adults ...
Nov 9 (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday approved Valneva's (VLS.PA) single-shot vaccine for individuals 18 years of age and older who are at increased risk of ...
The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for ...
Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the ...
The U.S. Food and Drug Administration on Thursday approved the first vaccine against chikungunya virus, a disease that is primarily transmitted to people through infected mosquito bites.
The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria. Valneva Austria's parent company is France's Valneva SE.
Nov. 10, 2023 -- The FDA on Thursday approved the first vaccine for the chikungunya virus, which is transmitted to humans through mosquito bites. The vaccine, called Ixchiq and produced by Valneva ...
Valneva (NASDAQ:VALN) announced on Friday its Ixchiq single-dose, live-attenuated vaccine against the chikungunya virus was approved by the U.S. FDA. Ixchiq is the world's first vaccine against ...
Nov 10 (Reuters) - French drugmaker Valneva said on Friday the U.S. Food and Drug Administration (FDA) has approved its Chikungunya single-dose vaccine in individuals aged 18 and above. The ...
